Table 4 Cost effectiveness results of the base case analysis
From: Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
Comparison | New technology | Comparator | Incremental costs | Incremental QALYs | Cost per QALY gained | |||
|---|---|---|---|---|---|---|---|---|
New tech | Comparator | Costs | QALYs | Costs | QALYs | |||
HPV9 girls | HPV4 girls | €183.29 | 27.53857 | €180.60 | 27.53797 | 2.69 | 0.0006 | €4483 |
HPV9 girls | HPV2 girls | €183.29 | 27.53857 | €188.92 | 27.53571 | −5.63 | 0.00286 | Cost saving |
HPV9 universal | HPV4 universal | €213.64 | 27.54041 | €206.63 | 27.53974 | 7.01 | 0.00067 | €10,463 |
HPV9 universal | HPV4 girls | €213.64 | 27.54041 | €180.60 | 27.53797 | 33.04 | 0.00244 | €13,541 |